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Abstract
Background: Precision interventions using biological data may enhance smoking treatment, yet
are understudied among smokers who are disproportionately-burdened by smoking-related
disease.

Author Manuscript

Methods: We surveyed smokers in the NCI-sponsored Southern Community Cohort Study,
consisting primarily of African American, low-income adults. Seven items assessed attitudes
towards aspects of precision smoking treatment, from undergoing tests to acting on results. Items
were dichotomized as favorable (5=strongly agree/4=agree) vs. less favorable (1=strongly
disagree/2=disagree/3=neutral); a summary score reflecting generalized attitudes was also
computed. Multivariable logistic regression tested independent associations of motivation
(precontemplation, contemplation, preparation) and confidence in quitting (low, medium, high)
with generalized attitudes, controlling for sociodemographic factors and nicotine dependence.
Results: Over 70% of respondents endorsed favorable generalized attitudes toward precision
medicine, with individual item favorability ranging from 64-83%. Smokers holding favorable
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generalized attitudes reported higher income and education (p’s < 0.05). Predicted probabilities of
favorable generalized attitudes ranged from 63% to 75% across motivation levels (contemplation
vs. precontemplation: Adjusted odds ratio [AOR]=2.10 [95%CI 1.36-3.25], p<.001; preparation vs
precontemplation: AOR=1.83 [95%CI 1.20-2.78], p=.005; contemplation vs. preparation:
AOR=1.15 [95%CI 0.75-1.77], p=.52) and from 59% to 78% across confidence (med vs low:
AOR=1.91 [95%CI 1.19-3.07], p=.01; high vs low: AOR=2.62 [95%CI 1.68-4.10], p<.001; med
vs high: AOR=0.73 [95%CI 0.48-1.11], p=.14).
Conclusions: Among disproportionately-burdened community smokers, most hold favorable
attitudes towards precision smoking treatment. Individuals with lower motivation and confidence
to quit may benefit from additional intervention to engage with precision smoking treatment.
Impact: Predominantly favorable attitudes towards precision smoking treatment suggest promise
for future research testing their effectiveness and implementation.

Author Manuscript

Racial, economic, and regional disparities remain in tobacco use, with minority, low-income,
and southern-dwelling smokers all bearing a disproportionate burden of smoking-related
disease and mortality (1,2). Precision medicine that tailors smoking treatment to individuals’
genetic characteristics is a promising approach for reducing smoking-related disparities.
However, it remains unclear whether precision approaches will be taken up and used among
populations of smokers who are disproportionately burdened by tobacco (i.e., based on their
race/ethnicity, income, region of the United States, or the intersection of these (1,2)).

Author Manuscript

Past work supports the efficacy of precision approaches in promoting smoking cessation
(3-9). Lerman et al (5) demonstrated that smokers with faster nicotine metabolism (assessed
by the nicotine metabolite ratio (NMR), a genetically informed biomarker of hepatic
nicotine metabolism) assigned to receive varenicline were twice as likely to quit smoking as
those assigned to the nicotine patch. Among slower metabolizers, these treatments were
equally effective, but side effects with varenicline were more pronounced. However, in that
study smokers were not informed of their NMR results, leaving open the question of how
they might react to this information if it were incorporated into smoking treatment. Other
work has demonstrated that smokers who received results from a commercially available test
for a gene-based lung cancer risk score (Respiragene) (7,8) were more likely to undergo
lung cancer screening, use nicotine replacement therapy, and quit smoking. Further
enthusiasm for these specific precision approaches is bolstered by evidence of their
acceptability among smokers (10-13).

Author Manuscript

However, for precision approaches to promote health equity, they must be broadly
implementable, especially among groups suffering from tobacco-related disparities.
Evidence-based treatments for smoking cessation are underutilized among
disproportionately burdened smokers (14-16) for many reasons, including unfavorable
attitudes towards some of these treatments (17-20). Research in other healthcare contexts
shows racial/ethnic minorities have more concerns about genetic testing and precision
medicine than Whites, believing genetic testing or precision medicine may be misused, lead
to racial discrimination, or do more harm than good (21,22). However, preliminary findings
support the acceptability of precision approaches for smoking among minorities. Shields et
al. (23) found that African American smokers were more likely than White smokers to be
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willing to undergo genetic testing to be matched to optimal treatment. Another small study
of primarily African-American smokers found that participants who had already expressed
interest in receiving genetic risk results responded favorably to them and that quit attempts
increased after receiving results (24). These preliminary findings support the hypothesis that
precision approaches for smoking will be equitably taken up and utilized.

Author Manuscript

Another key step to successful clinical translation is understanding potential predictors of
engagement in precision smoking treatment. Lack of motivation and confidence are known
barriers to successful smoking cessation, and may be used by smokers or their providers as
rationale to forego the use or offer of smoking treatments, respectively (25,26). However,
recent research and updated guidelines suggest that services should be offered to smokers
across the motivational spectrum (27-29). Understanding whether smokers lacking
motivation or confidence would be willing to use precision treatments could help researchers
and clinicians identify strategies to increase engagement in this population of smokers.
We build on existing knowledge by concurrently examining attitudes towards two promising
precision approaches (NMR, which can be leveraged to select pharmacotherapy, and genebased risk testing, Respiragene, which can be leveraged to enhance motivation to make
healthy behavior change) and behavioral changes based on these test results. We examine
these attitudes among participants of the Southern Community Cohort Study (SCCS), a
population of disproportionately burdened smokers. We hypothesized that precision smoking
treatment would generally be viewed favorably, and that favorable attitudes would be more
likely among motivated, confident smokers.

Methods
Author Manuscript

Study Population
The Southern Community Cohort Study (SCCS) is a prospective cohort study sponsored by
the National Cancer Institute and initiated in 2001 (30). The SCCS was established to
identify causes of disparities in cancer and other health outcomes. The cohort includes
approximately 85,000 adults throughout the southeastern United States that have been wellcharacterized by over 15 years of participation in the study. The cohort consists primarily of
African American, low-income adults, members of demographic groups that are traditionally
underrepresented in health research. A majority of the cohort was recruited at community
health centers, and nearly 25% of respondents currently reside in rural areas. The study also
features a large biorepository with genetic data for ~90% of participants.
Participants

Author Manuscript

Participants were eligible for inclusion in the current study’s Precision Smoking Cessation
Survey, collected in 2017, if they were active SCCS participants residing in Tennessee or
Mississippi and identified as current smokers in the SCCS Followup 3 survey, collected
between 2015 and 2018 (N=1407). A total of 988 responses to the Precision Smoking
Cessation Survey were collected, yielding a response rate of 70%. Of these, 143 were
excluded (72 had quit smoking since SCCS Followup 3; 31 lacked data on smoking status,
and 40 did not respond to at least 2/3rd of the precision medicine items, a requirement for
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inclusion in the analysis) yielding an analytic sample of 845 smokers. Compared to smokers
with complete data on attitudes towards precision medicine, those missing < 1/3rd of data
tended to have higher nicotine dependence, as defined by the Heaviness of Smoking Index
(X2=15.23, p<.001). Further exclusions based on missing data were made on an analysis-byanalysis basis (see Statistical Analyses). All participants provided written informed consent
before enrollment in the SCCS. This study was conducted in accordance with recognized
ethical guidelines (e.g., Declaration of Helsinki, CIOMS, Belmont Report, U.S. Common
Rule) and was approved by institutional review boards at Vanderbilt University, Meharry
Medical College, and Tennessee State University.
Measures

Author Manuscript

Attitudes towards Precision Medicine—Seven items assessed attitudes towards
different aspects of precision treatment of smoking (Supplementary Table 1). Items were
designed with iterative feedback from a Community Advisory Board consisting of current
and former smokers to ensure the use of simple, understandable language. They were
designed to capture attitudes towards both pharmacogenetics and gene-based lung cancer
risk assessment, with a focus on clinically relevant behaviors (i.e., taking the tests, taking
medication, getting lung cancer screening, and quitting smoking). At the time of survey
construction, Respiragene was commercially available as a buccal swab while NMR was
often conducted via blood test; item wording reflects these test modalities. Items were rated
on a 5-point scale (1=strongly disagree, 5=strongly agree), responses were dichotomized to
reflect favorable (4=agree, 5=strongly agree) vs. not favorable attitudes (1=strongly
disagree, 2=disagree, 3=neutral).

Author Manuscript

While each individual item taps into a different aspect of precision smoking treatment, they
theoretically also capture an underlying construct reflecting more generalized attitudes
towards precision smoking treatment. To create a measure of generalized attitudes (see
Statistical Analyses and Results), we first calculated the mean of all 7 items (mean=3.77,
SD=0.95) and dichotomized mean total scores to correspond to the cutoffs used for the
individual items reported above (<3.5=not favorable, ≥3.5=favorable), thus facilitating
comparison between individual items and the summary statistic.

Author Manuscript

Motivation to Quit—Assessment of motivation to quit was guided by the two items from
the transtheoretical model (31): “Are you thinking of quitting cigarettes in the next six
months?” (Yes/No), and, “Are you planning to quit smoking in the next 30 days?” (Yes/No),
producing three groups (precontemplation=not yet thinking of quitting;
contemplation=thinking about quitting in the next six months but not planning to quit in the
next 30 days; preparation=planning to quit in the next 30 days).
Confidence in Quitting—A single item assessed confidence in quitting, “I am confident
that I can quit smoking,” rated on a 5-point scale (1=strongly disagree to 5=strongly agree)
(32,33). Responses were categorized into low (disagree, strongly disagree), medium
(neutral), and high (strongly agree, agree) confidence levels.

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.
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Sociodemographics.: Sociodemographic items included age, sex, race and ethnicity, and
highest education completed (assessed at SCCS baseline, 2002–2009), annual household
income and insurance status (assessed at SCCS follow up, 2015–2018).
Nicotine Dependence.: Nicotine dependence was calculated via the Heaviness of Smoking
Index (HSI, (34)), a metric based on self-reported time to first cigarette (within 5 minutes,
6–30 minutes, 31–60 minutes, after 60 minutes) and number of cigarettes smoked per day.

Author Manuscript

Lung Cancer Risk.: Predicted lung cancer risk for each respondent was calculated using
the Tammemagi risk predictor, which incorporates age, education, race/ethnicity, body mass
index (BMI), family history of lung cancer, personal history of cancer, diagnosis of chronic
obstructive pulmonary disease (COPD), emphysema, or chronic bronchitis, current smoking
status, current cigarettes per day, and years smoked (35). These data were collected through
participation in the SCCS baseline and follow-up surveys. This calculated risk score was
included for descriptive purposes to better characterize the sample, but the study was not
designed to inform participants of this information. Because respondents were not informed
of their predicted lung cancer risk scores, it was not expected that the scores would be
associated with attitudes towards precision smoking treatment. Thus, this variable is not
included in hypothesis testing.

Author Manuscript

Statistical Analyses—Statistical analyses were conducted using IBM SPSS Statistics 25
and Stata 15 SE. We conducted an exploratory factor analysis and examined inter-item
correlations to calculate a summary score reflecting generalized attitudes towards precision
smoking treatment. Next, we tested whether generalized attitudes towards precision smoking
treatment differed across demographic and smoking-related factors, using t-tests for
continuous variables and chi-square tests for both ordinal and nominal variables. These
analyses used data from the full analytic sample (n=845).

Author Manuscript

Multivariable logistic regression tested associations between motivation (precontemplation,
contemplation, preparation) and confidence in quitting (low, medium, high) with generalized
attitudes towards precision treatment of smoking, adjusting for sociodemographic
characteristics (age, race, sex, education, insurance) and nicotine dependence. The effects of
these covariates were also explored. For each level of motivation and confidence, we
calculated the average predicted probability of holding favorable generalized attitudes using
the margins posttest in Stata. This test averages the estimates of each individual’s probability
of holding favorable generalized attitudes if all covariates are unchanged and the exposure
variable is set to a given value (e.g., low confidence). Respondents with missing data on
either confidence or motivation (n=50) or on one or more covariates (n=57) were excluded,
resulting in a sample of 738 smokers for this analysis. Compared to those with complete
data, smokers missing data tended to have lower levels of education (χ2(2, 823)=10.91, p=.
004) but were similar across other factors. Income was not included in this analysis due to
the amount of missing data in this variable. However, including income as an additional
covariate did not change the pattern of results from that reported below.
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Results
Attitudes towards Precision Treatment
Factor analysis of the seven survey questions relating to attitudes towards precision
treatment of smoking revealed that a single factor explained 61% of total variance in
responses. In the unrotated factor matrix, factor loadings for the seven individual items on
the first factor ranged from 0.43 to 0.93. Furthermore, inter-item correlations revealed
moderate to strong correlations across individual items (Table 1), and Cronbach’s alpha of
0.89 supported scaling items to form a single construct.

Author Manuscript

Overall, 71% of smokers held favorable generalized attitudes towards precision smoking
treatment (Figure 1). For individual items, favorability of each aspect of precision treatment
ranged from 64% to 83%. The blood test for pharmacotherapy selection based on nicotine
metabolism was less likely to be rated favorably (Item 2=64%, Item 1=69%) while the saliva
test for lung cancer risk was most likely to be rated favorably (Item 5=79%, Item 6=81%,
Item 7=83%). Within these categories, responses were well distributed. The modal
“favorable” response was “4=agree” for each item, although approximately 1/3 to 1/2 of
“favorable” responses indicated strong agreement. Within “not favorable” responses, strong
disagreement was the most common response to items 1–4, while a neutral response was
most common for items pertaining to the saliva testing for lung cancer risk (5-7).
Baseline Characteristics of the Sample and Relation to Attitudes

Author Manuscript

Smokers recruited through the SCCS were predominantly African American and lowincome. Approximately one third of the sample was considered at high risk of developing
lung cancer based on predicted lung cancer risk score (Table 2). Compared to respondents
without favorable generalized attitudes towards precision smoking treatment, those with
favorable attitudes tended to be younger, report higher income and education, have private
insurance or Medicare, have lower nicotine dependence, and have higher motivation and
confidence to quit smoking.
Multivariable Regression Results

Author Manuscript

Association between Motivation and Attitudes.—Controlling for sociodemographic
characteristics and nicotine dependence, the odds of endorsing favorable generalized
attitudes were directly related to motivation to quit (Table 3). Compared to smokers in
precontemplation, smokers in contemplation (adjusted odds ratio [AOR]=2.10 [95% CI
1.36–3.25], p=.001) and preparation (AOR=1.83 [95% CI 1.20–2.78], p=.005) had more
favorable generalized attitudes. Smokers in contemplation did not significantly differ from
those in preparation (AOR=1.15 [95% CI 0.75–1.77], p=.52). Adjusted predicted
probabilities of endorsing favorable attitudes were ≥63% across all levels of motivation (see
Figure 2).
Association between Confidence and Attitudes.—Odds of endorsing favorable
attitudes were also directly related to confidence in quitting (see Table 3). In adjusted
models, compared to smokers with low confidence, those with medium (AOR=1.91 [95% CI
1.19–3.07], p=.007) and high (AOR= 2.62 [95% CI 1.68–4.10], p<.001) confidence had
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more favorable generalized attitudes. Smokers with medium confidence did not significantly
differ from those high in confidence (AOR= 0.73 [95% CI 0.48–1.11], p=.14). Adjusted
predicted probabilities of endorsing favorable attitudes were ≥59% across all levels of
motivation (see Figure 2).
Associations between Demographic Factors, Nicotine Dependence and
Attitudes.—After adjustment, smokers who were younger (AOR=0.96 [95% CI 0.93–
0.99], p=.02), had greater than a high school education (vs. less than high school; AOR=1.61
[95% CI 1.03–2.54], p=.04), or had private insurance (AOR=2.29 [95% CI 1.00–5.23], p=.
05) remained more likely to hold favorable attitudes towards precision smoking treatment. In
addition, African Americans were 53% less likely to hold favorable attitudes than Whites
(AOR=0.47 [95% CI 0.27–0.83], p=.009). There was no significant effect of nicotine
dependence after adjustment for other variables in the model.

Author Manuscript

Discussion

Author Manuscript

Among over 800 low-income, southern-dwelling, predominantly minority smokers in the
Southern Community Cohort Study, 71% endorsed favorable attitudes towards precision
approaches to smoking cessation. Smokers with greater motivation and confidence had over
2 times the odds of endorsing favorable attitudes than those at the lowest levels. Yet
approximately 60% of those with the lowest levels of confidence and motivation still
endorsed precision approaches, suggesting that intervention research and clinical
implementation of precision approaches should be inclusive of smokers across the
motivational and confidence spectrums. Similarly, despite less positive attitudes toward
precision smoking treatment among older, African American, and less highly educated
smokers, endorsement remained generally high. Together, these findings provide evidence
that precision smoking treatment will be well-received and could promote behavior change
among disproportionately burdened smokers.

Author Manuscript

This study is the first to concurrently document the acceptability of NMR, a genetically
informed biomarker for nicotine metabolism, Respiragene, a gene-based lung cancer risk
assessment, and participants’ hypothetical estimates of their own behavior change based on
these tests results. Results add further evidence to the promise of using precision approaches
for smoking treatment among disproportionately burdened groups (23,24). The personalized
nature of these approaches may increase their acceptability relative to other existing
treatments such as counseling and medication, which tend to be viewed less favorably by
members of disproportionately burdened groups (17-20). Data also support combining
attitudes towards these varied aspects of precision treatment into a single measure of
generalized attitudes towards precision smoking treatment, which will facilitate
measurement and analysis of these and similar approaches in future work.
Results highlight the opportunity of integrating precision approaches into clinical care to
improve health outcomes. For example, past work suggests that lung cancer screening is
associated with 20% relative reduction in mortality (36), yet in 2016, only 1.9% of eligible
smokers were screened, with screening rates in the Southern U.S. being among the lowest
(37). Notifying patients of their lung cancer risk using Respiragene may motivate
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engagement in smoking treatment; 83% of respondents in our sample reported that they
would be more likely to get lung cancer screening if their genetic test result suggested they
were at high risk of lung cancer. Given that nearly 1/3 of the sample is considered at high
risk of developing lung cancer, this increased rate of lung cancer screening would likely
result in lives saved. In addition, 64% of smokers in this sample said they would take
medication based on results of a blood test, and matching patients to medication based on
NMR status can double the efficacy of medication for faster metabolizers while minimizing
side effects for slower metabolizers (5).

Author Manuscript

Integrating precision approaches with existing motivational and confidence-building tools
may increase the impacts of each. For example, motivational interviewing, a style of
counselling aimed at increasing motivation by addressing patients’ ambivalence towards
behavior change, has been widely applied in clinical settings with small to moderate effects
(38,39). These data suggest a threshold effect of increased motivation and confidence, with
more favorable attitudes among smokers with at least moderate (relative to low) levels of
motivation and confidence, but no added benefit of being highly motivated or confident. It is
possible that for smokers at the lowest levels of motivation and confidence, small increases
in these factors may be enough to facilitate engagement in precision treatment. Incorporating
precision approaches with motivational interviewing techniques may maximize impact on
smoking cessation for all smokers, but especially those from disproportionately burdened
groups who lack confidence or motivation. Yet another application of these tests lies in
improving efficiency of care by reducing waste and cost. For example, a two-fold greater
efficiency of lung cancer screening can be achieved by using this gene-based approach to
assessing lung cancer risk to identify who benefits most from lung cancer screening (40).

Author Manuscript
Author Manuscript

Though these data suggest that most smokers view precision smoking treatment favorably,
additional support may be necessary to engage smokers who are older, African American,
and do not have a high school degree. Sources of resistance to precision treatment are likely
to vary across these different aspects of identity, perhaps including perceived social norms,
access, or privacy concerns. If precision approaches are to narrow health disparities, future
work should examine means of further increasing their appeal to these groups of smokers.
For example, to influence perceived social norms, these results may be disseminated to
current smokers to demonstrate the social acceptability of precision smoking treatment
among their peers. To ensure equity in access, future work should examine the acceptability
and feasibility of implementing these approaches at the provider and system levels.
Healthcare systems, particularly in community settings most likely to serve smokers from
disproportionately burdened groups, may not have the infrastructure or resources in place to
implement precision approaches. Providers may not be well informed about the efficacy of
precision approaches or may believe some groups of patients will reject precision smoking
treatment. Providers may also require additional education or training regarding culturally
competent communication, which can address patients’ concerns about privacy or the
potential for harm.
Our study has several limitations. First, we did not assess actual behavior; thus, we cannot
maintain that respondents will take the tests for nicotine metabolism or lung cancer risk, or
that doing so will lead to improvements in lung cancer screening, cessation rates, or
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medication adherence. However, intentions such as those measured here can be powerful
predictors of behavior (41). Next, items related to Respiragene specified a buccal smear
(“saliva test”) and items related to NMR testing specified a blood test, confounding the type
of test with the mode of testing. Higher observed favorability ratings for risk assessment vs.
pharmacogenetics are likely due to preferences for less invasive buccal smear over blood
tests. As the field moves forward, these tests will likely be widely available using blood or
buccal swab samples, suggesting pharmacogenetics will be viewed even more favorably than
reported here. Next, while the sample of disproportionately burdened smokers is a strength,
these results may not generalize to other high-risk groups, such as low-income African
Americans in large urban centers or immigrant groups lacking English proficiency, and
future work should establish the likely acceptability of precision approaches among these
groups.

Author Manuscript
Author Manuscript
Author Manuscript

Despite these limitations, results have broad implications for research and clinical settings.
The study population is a significant strength. Participants were community smokers and
members of social groups traditionally underrepresented in healthcare research and at high
risk of suffering tobacco-related disparities. Understanding this group of smokers, their
attitudes towards precision smoking treatment, and variation in attitudes associated with
known barriers to cessation (e.g., motivation and confidence) lays the groundwork for
intervention research to examine the efficacy of precision approaches for equitable treatment
of smoking cessation. Further, data were collected through the Southern Community Cohort
Study, which has characterized participants over more than 15 years. We leveraged
previously collected data to accurately define smoking history and richly describe the
sample (e.g., calculate predicted lung cancer risk) with minimal additional respondent
burden. Further, the SCCS offers a large biorepository that can be leveraged for future
precision treatment approaches with Respiragene and the NMR. This work also has clinical
implications in that knowledge of the acceptability of genetic testing to assess lung cancer
risk and to support pharmacotherapy choice supports wide implementation of these
approaches. Future work would also benefit from the use of hybrid trial designs which
integrate effectiveness and implementation outcomes (42). Implementation theories and
frameworks like The Consolidated Framework for Implementation Research (CFIR) offer
guidance regarding potential facilitators and barriers to the successful implementation of
precision smoking treatment, such as an organization’s readiness for change and available
resources, patient and provider knowledge and attitudes, and the presence of individual
champions or supportive opinion leaders (43). Intervention studies of precision smoking
treatment would also be strengthened by the inclusion of implementation outcomes such as
reach among eligible patients, adoption by healthcare systems and individual providers, and
the sustainability of precision smoking treatment as a component of standard care (44). As
this research continues to clarify patient, provider, and system level barriers and facilitators
to precision smoking treatment, implementation science also offers strategies for addressing
these barriers and increasing engagement (45).
Our collective findings suggest that precision smoking treatment is favorably viewed and
likely to lead to behavior change among smokers who have historically been less successful
at quitting and are at especially high risk of suffering and mortality from smoking-related
disease. These data lay groundwork for future intervention research and support clinical
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.
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implementation of precision approaches by clarifying the promise of these approaches in
promoting health equity. Future research should focus on testing the comparative
effectiveness, as well as cost effectiveness and cost efficiency, of precision approaches in
promoting health behavior change, including lung cancer screening, medication adherence,
and smoking cessation. Research should also focus on implementation strategies that
support efficacy in community health settings to ensure equitable implementation and
dissemination of precision smoking treatments.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Acknowledgments
Author Manuscript

This work was supported by the National Cancer Institute (U54CA163072–09S1, PI: H. L. Moses, sub-project
6540, PI: H. A. Tindle; U54CA163069, PI: S. E. Adunyah, sub-project 6962, PI: M. Sanderson; U54CA163066, PI:
B. A. Husaini, sub-project 6610, PI: R. Selove), This project was further supported by the Vanderbilt Center for
Tobacco, Addiction, and Lifestyle (ViTAL; directed by H. A. Tindle). The Southern Community Cohort Study
(SCCS) is funded by grant R01CA92447 (PI: W. J. Blot and W. Zheng) from the National Cancer Institute at the
National Institutes of Health, including special allocations from the American Recovery and Reinvestment Act
(3R01CA092447–08S1). N. Senft was supported by the Agency for Healthcare Research and Quality (AHRQ)
under Award Number T32 HS026122. The content is solely the responsibility of the authors and does not
necessarily represent the official views of AHRQ. S. Warren Andersen is supported by R00CA207848,
P30CA014520 and the University of Wisconsin-Madison, Office of Vice Chancellor for Research and Graduate
Education with funding from the Wisconsin Alumni Research Foundation.” The project was supported by CTSA
award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. We also acknowledge a
Canada Research Chair in Pharmacogenomics (R. F. Tyndale).

References
Author Manuscript
Author Manuscript

1. Singh GK, Williams SD, Siahpush M, Mulhollen A. Socioeconomic, Rural-Urban, and Racial
Inequalities in US Cancer Mortality: Part I—All Cancers and Lung Cancer and Part II—Colorectal,
Prostate, Breast, and Cervical Cancers [Internet]. J. Cancer Epidemiol. 2011 [cited 2018 9 17].
Available from: https://www.hindawi.com/journals/jce/2011/107497/
2. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of
Progress. A Report of the Surgeon General [Internet]. Atlanta (GA): Centers for Disease Control
and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on
Smoking and Health; 2014 [cited 2019 5 20]. Available from: http://www.ncbi.nlm.nih.gov/books/
NBK179276/
3. Chen L-S, Baker TB, Grucza R, Wang JC, Johnson EO, Breslau N, et al. Dissection of the
Phenotypic and Genotypic Associations With Nicotinic Dependence. Nicotine Tob Res.
2012;14:425–33. [PubMed: 22102629]
4. Chen L-S, Horton A, Bierut L. Pathways to precision medicine in smoking cessation treatments.
Neurosci Lett. 2018;669:83–92. [PubMed: 27208830]
5. Lerman C, Schnoll RA, Hawk LW, Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine
metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for
smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med.
2015;3:131–8. [PubMed: 25588294]
6. Nichols JAA, Grob P, Kite W, Williams P, de Lusignan S. Using a genetic/clinical risk score to stop
smoking (GeTSS): randomised controlled trial. BMC Res Notes. 2017;10:507. [PubMed:
29061161]
7. Viron S, Heyden JV, Ambrosino E, Arbyn M, Brand A, Oyen HV. Impact of Genetic Notification on
Smoking Cessation: Systematic Review and Pooled-Analysis. PLOS ONE. 2012;7:e40230.
[PubMed: 22808123]

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.

Senft et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

8. Young RP, Hopkins RJ, Gamble GD. Clinical applications of gene-based risk prediction for lung
cancer and the central role of chronic obstructive pulmonary disease. Front Genet [Internet]. 2012
[cited 2019 1 23];3 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472507/
9. Bierut LJ, Tyndale RF. Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. Trends
Mol Med. 2018;24:187–96. [PubMed: 29307500]
10. Olfson E, Hartz S, Carere DA, Green RC, Roberts JS, Bierut LJ. Implications of Personal Genomic
Testing for Health Behaviors: The Case of Smoking. Nicotine Tob Res. 2016;18:2273–7.
[PubMed: 27613923]
11. Smerecnik C, Grispen JEJ, Quaak M. Effectiveness of testing for genetic susceptibility to smokingrelated diseases on smoking cessation outcomes: a systematic review and meta-analysis. Tob
Control. 2012;21:347–54. [PubMed: 21948804]
12. Wells QS, Freiberg MS, Greevy JR, Tyndale RF, Kundu S, Duncan MS, et al. Nicotine
Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT. Nicotine Tob Res Off J
Soc Res Nicotine Tob [Internet]. 2017 [cited 2018 10 8]; Available from: http://europepmc.org/
abstract/med/29059367
13. Chiu A, Hartz S, Smock N, Chen J, Qazi A, Onyeador J, et al. Most Current Smokers Desire
Genetic Susceptibility Testing and Genetically-Efficacious Medication. J Neuroimmune
Pharmacol Off J Soc NeuroImmune Pharmacol. 2018;13:430–7.
14. Cokkinides VE, Halpern MT, Barbeau EM, Ward E, Thun MJ. Racial and Ethnic Disparities in
Smoking-Cessation Interventions: Analysis of the 2005 National Health Interview Survey. Am J
Prev Med. 2008;34:404–12. [PubMed: 18407007]
15. Pacek LR, McClernon FJ, Bosworth HB. Adherence to Pharmacological Smoking Cessation
Interventions: A Literature Review and Synthesis of Correlates and Barriers. Nicotine Tob Res.
2018;20:1163–72. [PubMed: 29059394]
16. Trinidad DR, Pérez-Stable EJ, White MM, Emery SL, Messer K. A Nationwide Analysis of US
Racial/Ethnic Disparities in Smoking Behaviors, Smoking Cessation, and Cessation-Related
Factors. Am J Public Health. 2011;101:699–706. [PubMed: 21330593]
17. Christiansen B, Reeder K, Hill M, Baker TB, Fiore MC. Barriers to Effective Tobacco-Dependence
Treatment for the Very Poor. J Stud Alcohol Drugs. 2012;73:874–84. [PubMed: 23036204]
18. Hendricks PS, Westmaas JL, Park VMT, Thorne CB, Wood SB, Baker MR, et al. Smoking
Abstinence-related Expectancies among American Indians, African Americans, and Women:
Potential Mechanisms of Tobacco-related Disparities. Psychol Addict Behav J Soc Psychol Addict
Behav. 2014;28:193–205.
19. Ryan KK, Garrett-Mayer E, Alberg AJ, Cartmell KB, Carpenter MJ. Predictors of Cessation
Pharmacotherapy Use Among Black and Non-Hispanic White Smokers. Nicotine Tob Res.
2011;13:646–52. [PubMed: 21464200]
20. Rutten LJF, Augustson E, Moser RP, Beckjord EB, Hesse BW. Smoking knowledge and behavior
in the United States: sociodemographic, smoking status, and geographic patterns. Nicotine Tob
Res Off J Soc Res Nicotine Tob. 2008;10:1559–70.
21. Canedo JR, Miller ST, Myers HF, Sanderson M. Racial and ethnic differences in knowledge and
attitudes about genetic testing in the US: Systematic review. J Genet Couns. 2019;
22. Thompson HS, Valdimarsdottir HB, Jandorf L, Redd W. Perceived disadvantages and concerns
about abuses of genetic testing for cancer risk: differences across African American, Latina and
Caucasian women. Patient Educ Couns. 2003;51:217–27. [PubMed: 14630378]
23. Shields AE, Najafzadeh M, Schachter AB. Bumps along the translational pathway: anticipating
uptake of tailored smoking cessation treatment., Bumps along the translational pathway:
anticipating uptake of tailored smoking cessation treatment. Pers Med Pers Med. 2013;10, 10:813–
25.
24. Hartz SM, Olfson E, Culverhouse R, Cavazos-Rehg P, Chen L-S, DuBois J, et al. Return of
individual genetic results in a high-risk sample: enthusiasm and positive behavioral change. Genet
Med Off J Am Coll Med Genet. 2015;17:374–9.
25. Blumenthal DS. Barriers to the Provision of Smoking Cessation Services Reported by Clinicians in
Underserved Communities. J Am Board Fam Med. 2007;20:272–9. [PubMed: 17478660]

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.

Senft et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

26. Vogt F, Hall S, Marteau TM. General practitioners’ and family physicians’ negative beliefs and
attitudes towards discussing smoking cessation with patients: a systematic review. Addiction.
2005;100:1423–31. [PubMed: 16185204]
27. Jardin BF, Cropsey KL, Wahlquist AE, Gray KM, Silvestri GA, Cummings KM, et al. Evaluating
the Effect of Access to Free Medication to Quit Smoking: A Clinical Trial Testing the Role of
Motivation. Nicotine Tob Res. 2014;16:992–9. [PubMed: 24610399]
28. Fucito LM, Czabafy S, Hendricks PS, Kotsen C, Richardson D, Toll BA, et al. Pairing smokingcessation services with lung cancer screening: A clinical guideline from the Association for the
Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and
Tobacco: SRNT/ATTUD Screening Clinical Guideline. Cancer. 2016;122:1150–9. [PubMed:
26916412]
29. Burris JL, Heckman BW, Mathew AR, Carpenter MJ. A Mechanistic Test of Nicotine Replacement
Therapy Sampling for Smoking Cessation Induction. Psychol Addict Behav J Soc Psychol Addict
Behav. 2015;29:392–9.
30. Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study: investigating
health disparities. J Health Care Poor Underserved. 2010;21:26–37.
31. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process
of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of
change. J Consult Clin Psychol. 1991;59:295–304. [PubMed: 2030191]
32. Abrams DB, Niaura R, Brown RA, Emmons KM, Goldstein MG, Monti PM. The tobacco
dependence treatment handbook: A guide to best practices. New York, NY, US: Guilford Press;
2003.
33. Bandura A Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev.
1977;84:191–215. [PubMed: 847061]
34. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. The Fagerström Test for Nicotine
Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119–27.
[PubMed: 1932883]
35. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection
Criteria for Lung-Cancer Screening. N Engl J Med. 2013;368:728–36. [PubMed: 23425165]
36. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J
Med. 2011;365:395–409. [PubMed: 21714641]
37. Pham D, Bhandari S, Oechsli M, Pinkston CM, Kloecker GH. Lung cancer screening rates: Data
from the lung cancer screening registry. J Clin Oncol. 2018;36:6504–6504.
38. Heckman CJ, Egleston BL, Hofmann MT. Efficacy of motivational interviewing for smoking
cessation: a systematic review and meta-analysis. Tob Control. 2010;19:410–6. [PubMed:
20675688]
39. Hettema JE, Hendricks PS. Motivational interviewing for smoking cessation: A meta-analytic
review. J Consult Clin Psychol. 2010;78:868–84. [PubMed: 21114344]
40. Young RP, Hopkins RJ, Duan F, Chiles C, Aberle D, Gamble GD. Genetic-Based Approach to
Stratifying Risk of Lung Cancer Outperforms the Brock PLCO2012 Model - Optimization of CT
Screening Outcomes in the NLST-ACRIN Sub-Study (N=10,054). Am J Respir Crit Care Med.
2018;197:A4422.
41. Ajzen I The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211.
42. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation Hybrid
Designs. Med Care. 2012;50:217–26. [PubMed: 22310560]
43. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering
implementation of health services research findings into practice: a consolidated framework for
advancing implementation science. Implement Sci. 2009;4:50. [PubMed: 19664226]
44. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion
interventions: the RE-AIM framework. Am J Public Health. 1999;89:1322–7. [PubMed:
10474547]
45. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A refined
compilation of implementation strategies: results from the Expert Recommendations for
Implementing Change (ERIC) project. Implement Sci. 2015;10:21. [PubMed: 25889199]

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.

Senft et al.

Page 13

Author Manuscript
Author Manuscript

Figure 1.

Attitudes towards precision smoking treatment. Proportion of smokers endorsing favorable
(vs. not favorable) generalized attitudes (top row) and attitudes towards aspects of precision
smoking treatment.
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Figure 2.

Author Manuscript

Associations of motivation and confidence with generalized attitudes towards precision
smoking treatment. Predicted probabilities of having favorable generalized attitudes towards
precision smoking treatment across levels of motivation (upper panel) and confidence (lower
panel) are based on results of multivariable logistic regression adjusting for age, sex, race/
ethnicity, education, insurance, and nicotine dependence (n=738).
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Author Manuscript

Inter-item correlations for each aspect of attitudes towards precision smoking treatment*
1

2

3

4

5

6

Author Manuscript

1. If a blood test could help my doctor choose the best medicine for me to quit smoking, I
would take that blood test.

1

2. If a blood test could help my doctor choose the best medicine for me to quit smoking, I
would take that medicine.

0.88

1

3. I want to know how quickly my body breaks down nicotine.

0.76

0.75

1

4. I want to know if the speed at which my body breaks down nicotine affects my chances of
quitting smoking.

0.79

0.77

0.88

1

5. If a saliva test could use information on my genes to predict my risk of getting lung cancer,
I would take that saliva test.

0.43

0.40

0.41

0.43

1

6. If I took the saliva test and it showed that I was at high risk of lung cancer, I would be
more likely to quit smoking.

0.37

0.34

0.37

0.38

0.58

1

7. If I took the saliva test and it showed that I was at high risk of lung cancer, I would be
more likely to get lung cancer screening.

0.34

0.34

0.35

0.36

0.55

0.66

*

p<.001 for all inter-item correlations

Author Manuscript
Author Manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 February 01.

7

1

Senft et al.

Page 16

Table 2.

Author Manuscript

Sociodemographic characteristics, nicotine dependence (HSI), predicted lung cancer risk, motivation and
confidence across generalized attitudes towards precision treatment
Characteristic: N, %

1

Age (median, IQR)

1

Male sex

Total
(N=845)

Favorable
(n=599)

Not Favorable
(n=246)

P-Value

60 [56, 64]

59 [56, 64]

60 [57, 65]

.02

355 (42%)

248 (41%)

107 (44%)

.58

1

.09

Race

White

124 (15%)

98 (16%)

26 (11%)

African-American

705 (83%)

489 (82%)

216 (88%)

Other

13 (2%)

9 (2%)

4 (2%)

3

3

0

Missing

Author Manuscript

Education

1

.007

<High School

241 (29%)

156 (26%)

85 (35%)

High School or GED

317 (38%)

223 (37%)

94 (38%)

>High School

265 (31%)

205 (34%)

60 (24%)

Missing

22

15

7

2

.01

Household Income
<$15,000

526 (62%)

365 (61%)

161 (65%)

$15,000-$25,000

163 (19%)

118 (20%)

45 (18%)

$25,000-$50,000

64 (8%)

57 (10%)

7 (3%)

>50,000

25 (3%)

18 (3%)

7 (3%)

Missing

67

41

26

2

.04

Author Manuscript

Insured

Medicaid & Medicare

124 (15%)

81 (14%)

43 (18%)

Medicaid only

151 (18%)

103 (17%)

48 (20%)

Medicare only

176 (21%)

134 (22%)

42 (17%)

Private

74 (9%)

63 (11%)

11 (5%)

Military

38 (5%)

24 (4%)

14 (6%)

Other

66 (8%)

49 (8%)

17 (7%)

Uninsured

179 (21%)

125 (21%)

54 (22%)

Missing

37

20

17

3
Heaviness of Smoking Index (HSI)

.48

Author Manuscript

Low (0-1)

286 (34%)

196 (33%)

90 (37%)

Medium (2-4)

508 (60%)

368 (61%)

140 (57%)

High (5-6)

41 (5%)

30 (5%)

11 (5%)

Missing

10

5

5

Predicted Lung Cancer Risk

4

.90

<1.3%

508 (60%)

359 (60%)

149 (61%)

≥1.3%

263 (31%)

187 (31%)

76 (31%)
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Characteristic: N, %

Author Manuscript

Missing
Motivation

Total
(N=845)

Favorable
(n=599)

Not Favorable
(n=246)

74

53

21

3

<.001

Pre-contemplation

236 (28%)

142 (24%)

94 (38%)

Contemplation

262 (31%)

203 (34%)

59 (24%)

Preparation

325 (39%)

243 (41%)

82 (33%)

Missing

22

11

11

Confidence

P-Value

3

<.001

Low

167 (20%)

92 (15%)

75 (30%)

Medium

231 (27%)

160 (27%)

71 (29%)

High

416 (49%)

325 (54%)

91 (37%)

Missing

31

22

9

Author Manuscript

1

Assessed at baseline (2002-2009)

2

Assessed at SCCS followup 3 (2015-2018)

3

Assessed for the current study (2017)

4

Based on Tammemagi lung cancer risk calculator, risk threshold ≥1.3% recommended for cancer screening (35).

Author Manuscript
Author Manuscript
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Table 3:

Author Manuscript

Results of regression analysis predicting generalized attitudes towards precision smoking treatment (n=738)
1, 2

.
Adjusted Odds
Ratio (95% CI)

P-value

Motivation
Precontemplation

1.00 (referent)

Contemplation

2.10 (1.36-3.25)

0.001

Preparation

1.83 (1.20-2.78)

0.005

Confidence

Author Manuscript

Low

1.00 (referent)

Medium

1.91 (1.19-3.07)

0.007

High

2.62 (1.68-4.10)

<0.001

0.96 (0.93-0.99)

0.02

Age
Sex
Female

1.00 (referent)

Male

0.95 (0.67-1.36)

0.79

Race
White

1.00 (referent)

African Amer.

0.47 (0.27-0.83)

0.009

Other

0.55 (0.12-2.53)

0.44

Education
<High school

1.00 (referent)

High school

1.12 (0.74-1.71)

0.59

>High school

1.61 (1.03-2.54)

0.04

Author Manuscript

Insurance
Dual (Medicare/aid)

1.00 (referent)

Medicaid

1.14 (0.63-2.05)

0.67

Medicare

1.74 (0.98-3.09)

0.06

Private

2.29 (1.00-5.23)

0.05

Military

0.89 (0.38-2.04)

0.78

Other

1.21 (0.56-2.64)

0.63

None

1.00 (0.56-1.76)

0.99

Nicotine Dependence
Low

1.00 (referent)

Medium

1.35 (0.93-1.94)

0.11

High

1.54 (0.61-3.89)

0.36

Author Manuscript

1

Multivariable logistic regression tested associations between motivation and confidence in quitting with generalized attitudes towards precision
smoking treatment, adjusting for age, race, sex, education, insurance and nicotine dependence.

2

Restricted to smokers with complete data (n=738).
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